Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.

Money

Alto Neuroscience and Kyverna Therapeutics are following in the footsteps of CG Oncology, Metagenomi and Arrivent in seeking initial public offerings this year.

No longer on the periphery of the life sciences market, nonprofit groups are bridging the gaps in drug discovery and development.

FDA

After a quiet start to 2024, the FDA is expected to decide on three applications over the next two weeks, including one for a nasal powder migraine treatment.

AstraZeneca

The company said it has not seen any supply issues so far due to Red Sea shipping disruptions, a top executive told Reuters ahead of the World Economic Forum (WEF) on Monday.

female contraceptives, birth control

The current unmet needs in the female contraceptives market are similar to those that were present 10 years ago, according to GlobalData.

Merck

This approval marks the third indication for Keytruda in cervical cancer and the 39th indication for Keytruda in the United States.

As JPM week drew to a close, Lilly CEO David Ricks discussed what he sees in store for the biopharma industry.

Roche logo

The strategic acquisition provides Roche access to Carmot’s portfolio, which notably includes three lead molecules, all GLP-1 analogues, currently in the advanced stages of clinical trials for obesity and type 2 diabetes. It also positions the company on par with other industry leaders in the realm of GLP-1 analogues, such as Novo Nordisk, Eli Lilly and others.

Novartis

Dropping the potential Cytokinetics buy runs contrary to Novartis’ recent dealmaking frenzy, which included the acquisition of Calypso and three research collaborations.